Table 6.

Effects of Caspase and Granzyme B Inhibitors on SAS-1 and SAS-2 Hydrolytic Activity

		Percent Activity of Noninhibited
Inhibitor	Preferred Protease Target	SAS-1	SAS-2
No inhibitor	-	100% ± 3.0%	100% ± 2.6%
Ac-VAD-CMKa	Pan-Caspase	1% ± 0.6%	1% ± 0.1%
B-YVAD-CMKa	Caspase-1	1% ± 0.1%	1% ± 0.0%
Ac-WEHD-CHOa	Caspase-1	1% ± 0.5%	1% ± 1.2%
Ac-LDESD-CHOa	Caspase-2	39% ± 2.4%	49% ± 4.4%
Ac-VDVAD-CHOa	Caspase-2	1% ± 0.9%	2% ± 0.8%
Ac-DEVD-CMKa	Caspase-3	90% ± 4.9%	91% ± 5.6%
Ac-DMQD-CHOa	Caspase-3	1% ± 0.7%	1% ± 0.4%
Ac-LEVD-CHOa	Caspase-4	1% ± 0.2%	1% ± 0.9%
Ac-VEID-CHOa	Caspase-6	1% ± 0.2%	1% ± 0.8%
Ac-IETD-CHOa	Caspase-8	1% ± 0.4%	1% ± 1.5%
Ac-LEHD-CMKa	Caspase-9	47% ± 1.9%	58% ± 5.2%
Ac-LEED-CHOa	Caspase-13	68% ± 3.2%	67% ± 4.7%
Z-AAD-CMKa	Granzyme B	1% ± 0.6%	1% ± 1.0%

Enzymes were preincubated with 200 μM inhibitor for 2 h and then assayed for Z-VAD-AFC hydrolytic activity for 1 h.

Z, benzyloxycarbonyl; Ac, acetyl; B, biotin.

^aRecognition sequence in single-letter amino acid code.